Advertisement

Topics

Blueprint Medicines Announces Enrollment of First Patient in Phase 1 Clinical Trial for BLU-667

12:14 EDT 20 Mar 2017 | PR Newswire
This article has expired, however you can still download the PDF.
Preview:
CAMBRIDGE, Mass., March 20, 2017 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced that it has dosed the fir...

Other Sources for this Article

NEXT ARTICLE

More From BioPortfolio on "Blueprint Medicines Announces Enrollment of First Patient in Phase 1 Clinical Trial for BLU-667"

Quick Search
Advertisement
 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Gilotrif (afatinib)
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...